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Heparin induced thrombocytopenia
Heparine bağlı trombositopeni
Yunus Nazlı1, Necmettin Çolak1, Selim Çolak2, Ömer Çakır1
ÖZET
Heparine bağlı trombositopeni (HBT) heparin tedavisinin 
nadir fakat ciddi bir protrombotik yan etkisidir. Bu durum 
platelet faktör 4 ve heparin komplekslerine karşı trombosit 
aktive edici antikorlar tarafından indüklenir. Tanı hastalık 
olasılığının  klinik  değerlendirmesi  ve  laboratuvar  test-
lerine  dayanmaktadır.  Erken  tanı,  heparin  kullanımının 
kesilmesi  ve  müteakiben  alternatif  antikoagülan  ilaçlar 
ile tedavi trombüs oluşumu, ekstremite amputasyonu ve 
ölüm gibi ciddi komplikasyonların önlenmesi için önemli 
adımlardır. Bu derlemede, HBT’nin klinik özelliklerini ta-
nımlamak ve onun yönetimi için mevcut verileri özetleme-
yi amaçladık.
Anahtar sözcükler:  Heparin,  trombositopeni,  kardiyak 
cerrahi.
ABSTRACT
Heparin-induced thrombocytopenia (HIT) is a rare but se-
rious prothrombotic adverse effect of heparin treatment. It 
is induced by platelet-activating antibodies against com-
plexes of platelet factor 4 and heparin. Diagnosis rests on 
a clinical assessment of disease probability and labora-
tory testing. Prompt diagnosis of HIT, discontinuation of 
heparin use, and subsequent treatment with alternative 
anticoagulant drugs are essential steps to prevent serious 
complications such as thrombus formation, limb amputa-
tion, and death. In this review, we describe the clinical 
features of HIT and to summarize the data available for 
its management. J Clin Exp Invest 2014; 5 (1): 137-144
Key words: Heparin, thrombocytopenia, cardiac surgery.
INTRODUCTION
Heparin-induced thrombocytopenia (HIT) is a clini-
copathologic disorder initiated by heparin exposure 
and characterized by thrombocytopenia and para-
doxical  thrombotic  events.  This  disorder  may  be 
classified into 2 categories: type I and type II (Table 
1).
Table 1. Distinguishing characteristics of the 2 types of heparin-induced thrombocytopenia
Type I Type II
Frequency (%) 10-20 1-3
Timing of onset (day) 1-4 5-10
Nadir platelet count  100.000/microL (mild) Generally >20,000/microL; median nadir 60,000/microL
Antibody mediated  No Yes
Thromboembolic sequelae None 30 to 80%
Hemorrhagic sequelae None Rare
Management Observation Stopping of heparin, anticoagulation alternatively to heparin 
for preventing thrombosis
Type I [HIT-I]. The most common form of throm-
bocytopenia, of no clinical consequence, is typically 
characterized by a mild decrease in platelet count 
that consists within the first 2 days after heparin ini-
tiation and frequently returns to normal with contin-
ued heparin administration. The mechanism of the Nazlı et al. Heparin induced thrombocytopenia 138
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thrombocytopenia is non-immune and appears to 
be due to a direct effect of heparin on platelet ac-
tivation.
Type  II  [HIT-II]. The  less  common  and  more 
severe form is an immune-mediated disorder char-
acterized by the formation of antibodies against the 
heparin-platelet factor 4 (H-PF) complexes. It has 
also been called heparin induced thrombocytopenia 
and thrombosis (HITT), heparin-associated immune 
thrombocytopenia, and white clot syndrome. White 
clot syndrome means to platelet-rich arterial throm-
bosis  (rather  than  fibrin-rich  venous  thrombosis), 
which consists with high frequency in patients who 
develop this disorder [1-4].
PATHOPHYSIOLOGY
Heparin binds to platelets in the absence of an an-
tibody and releases small amounts of platelet fac-
tor (PF) 4 (as occurs in heparin-associated throm-
bocytopenia). PF4 heatedly binds heparin to form 
H-PF4 complex, which is antigenic in some people. 
In these people IgG antibodies to the H-PF4 com-
plex are occurred within 5 to 15 days after exposure 
to heparin and continue to circulate in the absence 
of more heparin for approximately 3 to 6 months. 
Anti-H-PF4 IgG antibodies plus H-PF4 complexes 
form HIT complexes, which unite IgG Fc terminals 
to platelet Fc receptors (Figure 1). This binding vig-
orously stimulates platelets to release more PF4. A 
self-perpetuating, accelerating cascade of platelet 
activation, release, and aggregation ensues. Since 
platelet granules comprise several procoagulatory 
proteins  (e.g.,  thrombin,  factor  V,  fibrinogen,  and 
von Willebrand factor), release also activates co-
agulation proteins to generate thrombin [1,2,4,5].
Figure 1. The generation of 
HIT complexes. Read each 
horizontal group of three left 
to right beginning at top left. 
INCIDENCE AND RISK FACTORS
A critical evaluation of immune-mediated HIT sug-
gests  a  frequency  of  0.2  to  5.0%  in  patients  ex-
posed to heparin for more than 4 days. There are 
three factors in addition to longer duration of treat-
ment that are most vigorously associated with the 
development of HIT (Table 2,3).
1. Use of unfractionated heparin (UFH) rather 
than low molecular weight heparin (LMWH)
2. Surgical rather than medical patients
3. Female rather than male patients update
Antibodies are more likely to form in patients 
undergoing open heart surgery than in orthopedic 
patients. But, among those in whom antibodies do 
form, orthopedic patients are more likely to develop 
HIT than undergoing open heart surgery.
HIT is unusual among patients < 40 years of 
age as well as in women following delivery. Occa-
sional patients have developed this disorder after 
exposure to as little as 250 units from a heparin 
flush or after the use of heparin-coated catheters 
[3,4,6-8].Nazlı et al. Heparin induced thrombocytopenia 139
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Risk factors
Heparin exposure > 4 days
Recent heparin (past 100 day)
Exposure to unfractionated heparin (versus low molecular weight heparin)
Postoperative patients (orthopedic > cardiac and vascular surgery)
Intravenous heparin administration (versus subcutaneous)
Dose of heparin (therapeutic > prophylaxis > flushes)
Female sex, female > male
Age > 40 years
platelet count of about 60,000/microL. As a result, 
spontaneous hemorrhage is rare [4,8].
Cardiac surgery patients
A major fall in the platelet count of approximately 
40 to 50 percent occurs universally during the first 
72 hours following open heart surgery, due at least 
in part to prolonged contact of platelets with the ar-
tificial surface of the extracorporeal circuit. These 
patients  generally  take  large  amounts  of  unfrac-
tionated heparin, a setting in which the incidence 
of HIT antibodies is as high as 25 to 70 percent by 
immunoassay and 4 to 20 percent by platelet acti-
vation assay. Since several other potential causes 
of thrombocytopenia are frequently present, it is dif-
ficult to determine whether or not HIT is present in 
these patients.
While this question has not been satisfactorily 
settled, the presence of a secondary decrease in 
the platelet count ≥ 50 percent that begins between 
the 5th and 10th postoperative day appears to be 
highly predictive of HIT [3,4].
Thrombosis
The major clinical problem associated with HIT is 
thrombosis/thromboembolism, venous, arterial, and 
Table 2. Risk factors for HIT
Table 3. Incidence of HIT accord-
ing to patient population and hep-
arin exposure-risk ratios
Examples of patient groups with risk estimated to be > 1%
Postoperative patients taking prophylactic dose UFH > 4 day
Postoperative patients taking therapeutic dose UFH > 4 day
Examples of patient groups with risk estimated to be 0.1-1%
Medical/obstetric patients taking prophylactic or therapeutic dose UFH > 4 day
Postsurgery patients taking LMWH > 4 day
Postsurgery patients taking UFH “flushes” > 4 day
Medical/obstetric patients taking LMWH after first taking UFH
Examples of patients groups with risk estimated to be < 0.1%
Medical/obstetric patients taking LMWH > 4 day
Medical/obstetric patients taking only heparin flushes
Any patient taking UFH or LMWH < 4 day
UFH: Unfractionated heparin, LMWH: low-molecular-weight heparin
CLINICAL MANIFESTATIONS
Onset time
Immune-mediated HIT consists 5 to 10 days after 
the  initiation  of  heparin  treatment.  Onset  after  2 
weeks is rare, an observation that correlates with 
serologic  tests  showing  that  heparin-dependent 
antibodies generally develop between days five to 
eight after exposure to heparin, but rarely later. Ear-
lier onset of HIT can be seen if the patient had been 
treated with heparin in the prior 1 to 3 months and 
still has circulating HIT antibodies.
a. Early onset HIT: It (median time of platelet 
fall 10 hours after the start of heparin administra-
tion) can be occurred in about 30 percent of patients 
with persistent antibodies due to heparin treatment 
within the prior 1 to 3 months.
b. Delayed onset HIT: It, in which thrombocyto-
penia and thrombosis, occur after heparin has been 
withdrawn (average of 9 days, 5 to 19 days). 
Degree of thrombocytopenia
Thrombocytopenia and/or a decrease in the plate-
let count greater than 50 percent, due to immune-
mediated HIT is uncommonly serious, with plate-
let counts typically >20,000/microL and a median Nazlı et al. Heparin induced thrombocytopenia 140
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intracardiac. The certain mechanism of this hyper-
coagulable state are the release of procoagulants 
from activated platelets, the generation of platelet 
microparticles, fragments of the platelet membrane. 
Since HIT antibodies also bind to heparan sulfate 
on the surface of endothelial cells, thrombosis can 
be based on endothelial cell activation and/or in-
creased tissue factor and thrombin generation due 
to endothelial cell injury.
Among patients taking heparin for thrombopro-
phylaxis or treatment, the first sign of HIT generally 
is the development of thrombocytopenia. If such a 
patient develops an initial or recurrent thrombotic 
event, the presence of thrombocytopenia suggests 
that it is due to HIT rather than failure of anticoagu-
lation. The major manifestations of venous thrombo-
sis are deep vein thrombosis (DVT) and pulmonary 
thromboembolism. Pulmonary thromboembolism is 
the most common life-threatening event, occurring 
in 25 percent of patients. Other manifestations of 
venous thrombosis involve venous limb gangrene 
(distal ischemic necrosis after DVT) and cerebral 
sinus  thrombosis.  Upper  extremity  DVT  has  also 
been reported in HIT, but is less common than lower 
extremity DVT.
Arterial  thrombosis,  although  less  common, 
may lead to a variety of clinical manifestations in-
volving  stroke,  myocardial  infarction,  acute  limb 
ischemia from peripheral arterial occlusion, or organ 
infarction (mesentery, kidney) [4].
Skin necrosis
Affected areas are usually fat-rich, such as the ab-
domen, as in warfarin-induced necrosis. However, 
the  distal  extremities  and  the  nose  may  also  be 
included. The appearance of erythema is followed 
by  purpura  and  hemorrhage  leading  to  necrosis. 
Although the lesions appear similar to warfarin-in-
duced skin necrosis, deficiencies of the natural anti-
coagulants are not present.
Other complications
Other unusual complications of HIT include adrenal 
hemorrhage secondary to adrenal vein thrombosis, 
and transient global amnesia [4,6,7].
DIAGNOSIS
Suspecting HIT
The first step in establishing a diagnosis of HIT is 
suspecting the presence of this disorder. Any one of 
the following scenarios could raise the possibility of 
HIT in a patient begun on heparin treatment within 
the preceding 5 to 10 days, or in a patient taking 
prolonged therapy with LMWH; 
1) Onset of else unexplained thrombocytope-
nia, 
2)  Arterial  or  venous  thrombosis  associated 
with thrombocytopenia, 
3) A  platelet  count  which  has  fallen  50%  or 
more from a previous value, even if absolute throm-
bocytopenia is not present, 
4)  Necrotic  skin  lesions  at  heparin  injection 
sites, 
5)  Acute  systemic  (anaphylactoid)  reactions 
(eg,  fever/chills,  tachycardia,  hypertension,  dys-
pnea,  cardiopulmonary  arrest)  occurring  after  IV 
heparin bolus administration.
The diagnosis of HIT is firstly made on clinical 
grounds, because the assays with the highest sen-
sitivity  and  specificity  cannot  be  readily  available 
and have a slow return time. The most specific diag-
nostic laboratory tests for HIT involve serotonin re-
lease assays, heparin-induced platelet aggregation 
assays, and solid phase immunoassays (Figure 2).
To aid in the diagnosis of HIT, a pretest clini-
cal score called the ‘‘4Ts’’ was developed and vali-
dated. A score is calculated based on the following 
4 categories (Table 4): 
1. Degree of thrombocytopenia, 
2. Timing of platelet count fall, 
3. Clinical sequelae such as thrombosis, and 
4. Presence of other etiologies of thrombocy-
topenia
Laboratory tests
Various laboratory tests are available to diagnose 
HIT and are broadly classified into functional and 
antigen-based  assays.  Two  standard  reference 
functional assays are the serotonin release assay 
(SRA),  which  has  high  sensitivity  and  specificity 
(both  95%)  when  performed  at  experienced  cen-
ters, and the heparin-induced platelet aggregation 
(HIPA) assay, which is specific (90 %) but not sensi-
tive. Due to limited ability of many clinical labora-
tories to perform these functional tests, a commer-
cially-available  ELISA  immunoassay  that  detects 
antibodies against the H-PF4 complex is frequently 
used  instead.  The  ELISA  is  a  sensitive  antigen-
based assay (90%) and has a high negative pre-
dictive value (95%) but low specificity, and hence, 
may be falsely positive, detecting non-pathogenic 
antibodies in patients without clinical evidence of 
HIT (Table 5) [3,6-8].Nazlı et al. Heparin induced thrombocytopenia 141
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Figure 2. Approach 
to  the  patient  with 
suspected  heparin 
induced  thrombo-
cytopenia. 
* Observation could be chosen only if patient is at high risk for bleeding. Otherwise treatment (anticoagulation with the 
agents listed) is preferred until the platelet count has returned to normal.
HIPA: Heparin-induced platelet aggregation assay; H-PF4 Ab: Heparin-platelet factor 4 antibody.
Table 4. The 4Ts assessment tool for patients with suspected HIT
Category 2 Point 1 Point 0 Point
Thrombocytopenia
50 % fall and platelet nadir 
≥20 x109/l
30-50% fall or platelet nadir 10-19 
x109/l
• < 30% platelet fall
• Any platelet fall with nadir 
<10 x109/l
Timing of platelet 
count fall or other 
sequelae
• Platelet fall day 5-10 after 
starting of heparin
• Platelet fall within 1 day 
of starting of heparin AND 
heparin exposure within 
past 5-30 days
• Consistent with platelet fall days 
5-10 but not clear (e.g., missing 
counts)
• Platelet fall within 1 day of starting 
of heparin AND exposure to heparin 
in past 31-100 days
• Platelet fall after day 10
Platelet fall day ≤ 4 without 
exposure to heparin in past 
100 days
Thrombosis or other 
sequelae
(e.g. skin lesions)
• Confirmed new thrombo-
sis (venous or arterial)
• Skin necrosis at injection 
site
• Anaphylactoid reaction to 
IV heparin bolus
•Adrenal hemorrhage
• Recurrent venous thrombosis in a 
patient taking therapeutic anticoagu-
lants
• Suspected thrombosis (awaiting 
confirmation with imaging)
• Erythematous skin lesions at hepa-
rin injection sites
Thrombosis suspected
Other cause for
thrombocytopenia
not evident
No alternative explanation 
for platelet fall is evident
Possible other cause is evident:
• Sepsis without proven microbial 
source
• Thrombocytopenia associated with 
initiation of ventilator
Exact other cause is present
Pretest probability score: 6-8 = High; 4-5 = Intermediate; 0-3 = Low.Nazlı et al. Heparin induced thrombocytopenia 142
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Table 5. Laboratory tests
Washed-platelet activation assays
SRA (Serotonin release assay ) Sensitivity and specificity, > 95%
HIPA (Heparin-induced platelet aggregation) Specificity (> 90%), not sensitivity 
Antigen assays ELISA immunoassay Sensitivity (90%), not specificity
be avoided since it may crossreact with the heparin-
induced antibodies. In the other hand, heparin stop-
ping alone is frequently not sufficient; since these 
patients remain at risk for subsequent thrombosis 
(30 day risk of thrombosis is 53 percent).
TREATMENT
The initial intervention in a patient with HIT could be 
prompt stopping of all exposure to heparin, involving 
heparin-bonded catheters and heparin flushes (eg, 
for arterial lines or heparin locks). LMWH could also 
Table 6. Non-heparin anticoagulants for use in HIT
Anticoagulant Argatroban Lepirudin Bivalirudin Danaparoid Fondaparinux
Activity DTI DTI DTI Factor Xa inhibitor Factor Xa inhibitor
Route of
administration  iv iv, sc iv iv, sc sc
Half-life
(minute/hour) 40-50 min 80 min 25 h 18-24 h 17-20 h
Monitoring aPTT aPTT aPTT Anti factor Xa level Anti factor Xa level
Effect on INR +++ + ++ 0 0
Dosing in HIT
Initial infusion rate 
2 µg/kg/min IV 
(no initial bolus); a 
reduced initial infu-
sion rate (0.5-1.2 
µg/kg/min) is ap-
propriate in certain 
patient popula-
tions*
Bolus 0.2-0.4 mg/
kg IV; maximum 
initial infusion 
rate 0.10 mg/kg/h 
IV (target, 1.5-2.0 
x patient’s base-
line or mean of 
laboratory normal 
range)
Initial infusion 
rate 0.15-0.20 
mg/kg/h IV (tar-
get, 1.5-2.5 x pa-
tient’s baseline or 
mean of labora-
tory normal range 
(no initial bolus)
Bolus: 2,250 U IV; 
infusion, 400 U/h - 4 
h, then 300 U/h x 4 h, 
then 200 U/h IV, sub-
sequently adjusted by 
anti-Xa levels (target, 
0.5-0.8 anti-XaU/mL)
Not established 
for HIT (<50 kg:5 
mg/day 50-100 kg: 
7.5 mg/day, >100 
kg: 10 mg/day SC)
Crosses placenta Unclear Unclear Unclear No Yes
Dialyzable 20% High-flux dialyzers 25% Yes 20%
Elimination
(half-life)
Hepatobiliary
(40-50 min)
Renal (80 min)
Both enzymic 
(80%) and renal 
(20%) metabo-
lism (25 min)
Renal (24 h, anti-Xa 
activity)
Renal (17-20 h)
DTI: Direct thrombin inhibitor *Patients with heart failure, multiple organ system failure, severe anasarca, and during 
the early post-cardiac surgery period.
There are a number of recommended alterna-
tive anticoagulants to heparin in a patient with HIT: a 
direct thrombin inhibitor such as lepirudin (recombi-
nant hirudin), bivalirudin, argatroban; fondaparinux; 
or danaparoid (Table 6). Whichever alternative an-
ticoagulant is used, it is important to administer it in 
suitable therapeutic doses as discussed below, as 
there is evidence for therapy failure in cases where 
doses deemed suitable for prophylaxis in other cir-
cumstances have been used in active HIT.
For patients with vigorously suspected or con-
firmed HIT who do not have active hemorrhage, pro-
phylactic platelet transfusions could not be given.
For patients with HIT, whether or not there is 
clinical evidence of lower extremity DVT, routine ul-Nazlı et al. Heparin induced thrombocytopenia 143
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trasound scan of the lower extremity veins are rec-
ommended for investigation of DVT. 
Women with HIT in pregnancy could be treated 
with a non-cross reacting anticoagulant. Danaparoid 
could  be  used  where  available  and  fondaparinux 
also considered.
If the patient has taken a vitamin K antagonist 
at the time of diagnosis it could be reversed by ad-
ministering intravenous vitamin K [3,4,9].
Warfarin and HIT
Warfarin could be initiated in a patient with HIT only 
when both of the following have been accomplished; 
[1] The patient has been stably anticoagulated with 
a  thrombin-specific  inhibitor,  and  [2]  The  platelet 
count has increased to at least 150,000/microL.
There could be a minimum of 5 days of over-
lapping  treatment  before  the  thrombin  inhibitor  is 
discontinued. The initial use of warfarin alone for a 
patient diagnosed with HIT could be avoided since 
warfarin treatment may increase the risk of venous 
limb gangrene in patients with DVT through its rapid 
lowering of protein C levels.
When the above 2 goals have been reached 
and warfarin treatment is started, high initial doses 
(eg, ≥10 mg/day) could be avoided to minimize the 
transient hypercoagulable state induced by the rap-
id decline in protein C levels. Accordingly, warfarin 
could be started at low maintenance doses of ≤5 
mg/day (or phenprocoumon ≤6 mg/day). The target 
range  for  anticoagulation  with  warfarin  treatment 
could be an international normalized ratio (INR) in 
the range of 2.0 to 3.0. [3,4,7].
The  length  of  therapy  with  warfarin  has  not 
been defined in any prospective study, but in view 
of the high risk of thrombosis within 30 days of the 
diagnosis of HIT, anticoagulation with warfarin could 
probably be continued for at least 2 to 3 months, 
and for at least 3 to 6 months if a thrombotic event 
has occurred [4].
SPECIAL POPULATION
Cardiac surgery and HIT
1. Patients with previous HIT undergoing open heart 
or vascular surgery
a) For patients with a history of HIT who are HIT an-
tibody negative and require open heart surgery, we 
recommend the use of UFH over an anticoagulation 
without heparin (Grade 1B).
b) For patients with a history of HIT who are anti-
body positive by PF4-dependent EIA but antibody 
negative by washed platelet activation assay, we 
recommend the use of UFH over an anticoagulation 
without heparin (Grade 2C).
In open heart surgery, there is a rationale and some 
data that support the safe use of UFH in patients 
with prior HIT; 
1)  HIT  antibodies  are  transient,  with  the  median 
time to antibody disappearance of 50 to 80 days, 
2) In rapid-onset HIT, there is not a strong associa-
tion with remote (> 100 days) previous heparin ex-
posure, 
3) Short term re-exposure to heparin for <4 days, 
such  as  for  open  heart  surgery,  can  be  possible 
without triggering another episode of HIT in patients 
with a history of HIT but no detectable HIT antibod-
ies, 
4) The  limited  experience  with  alternative  antico-
agulants for open heart surgery, and the inability to 
readily reverse their anticoagulant effects following 
surgery are important drawbacks, 
5)  The  risk  of  perioperative  complications,  par-
ticularly major hemorrhage (and, potentially, cata-
strophic  intraoperative  cardiopulmonary  bypass 
[CPB] thrombosis), is higher with the non-heparin 
anticoagulants.
These patients must be avoided UFH before 
and after open heart surgery, alternative anticoagu-
lants are recommended in this periods.
2. Patients with acute or subacute HIT under-
going cardiac surgery
a) For patients with acute HIT (thrombocytope-
nic, HIT antibody positive) who require open heart 
surgery, we recommend one of the following alter-
native anticoagulant approaches: delaying surgery 
(if possible) until HIT has resolved and antibodies 
are negative (see 1a) or weakly positive (see 1b) 
[Grade 1B]; using bivalirudin for intraoperative an-
ticoagulation during CPB (Grade 1B) or during off-
pump open heart surgery [Grade 1B].
b)  For  patients  with  subacute  HIT  (platelet 
count recovery, but continuing HIT antibody posi-
tive), we recommend delaying surgery (if possible) 
until HIT antibodies (washed platelet activation as-
say) are negative, then using heparin (see 1) over 
using  a  non-heparin  anticoagulant  [Grade  1C].  If 
surgery cannot be delayed, we suggest the use of a 
non-heparin anticoagulant (see 2a) over the use of 
UFH [Grade 2C] [3,4,6,8,10,11] (Table 7).Nazlı et al. Heparin induced thrombocytopenia 144
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Table 7. Anticoagulant protocol example used for cardiac surgery
Preferred
(level 1) options  Protocol Comments
UFH  Standard UFH dosing for CPB Avoid UFH before and after open heart surgery
Bivalirudin
Off-pump: bolus 0.75 mg/kg, then 1.75 mg/kg/h 
infusion to maintain
ACT > 300; 
CPB: 1 mg/kg bolus, 50 mg bolus added to 
priming solution of CPB, 2.5 mg/kg/h infusion, 
additional 0.1-0.5 mg boluses to maintain ACT > 
2.5-fold baseline ACT
Shorter t1⁄2 (25 min) and minor renal excretion 
(20%) are advantageous for cardiac surgery; avoid 
using patient blood for testing graft patency or for 
cardioplegia solution (as clots can form in stag-
nant, bivalirudin-anticoagulated blood); special ma-
neuvers needed to prevent stasis and consequent 
clotting of CPB circuit during or after surgery
UFH: Unfractionated heparin, ACT: Activated coagulation time, CPB: Cardiopulmonary bypass
Coagulation  monitoring.  St.  Luis,  Missuiri:  Elsevier 
Press, 2011:496-519.
3. Linkins LA, Dans AL, Moores LK, et al. American Col-
lege of Chest Physicians. Treatment and prevention 
of heparin-induced thrombocytopenia: Antithrombotic 
Therapy and Prevention of Thrombosis, 9th ed: Ameri-
can  College  of  Chest  Physicians  Evidence-Based 
Clinical  Practice  Guidelines.  Chest  2012;141:e495-
530.
4.  Coutre  S.  Heparin  induced  thrombocytopenia.  Nov 
2012.  http://www.uptodate.com/contents/heparin-in-
duced-thrombocytopenia
5.  Warkentin  TE,  Eikelboom  JW.  Who  is  (still)  getting 
HIT? Chest 2007;131:1620-1622.
6.  Watson  H,  Davidson  S,  Keeling  D.  Guidelines  on 
the  diagnosis  and  management  of  heparin-induced 
thrombocytopenia:  second  edition.  Br  J  Haematol 
2012;159:528-540.
7.  http://www.thd.org.tr/thdData/Books/130/bolum-ii-hep-
arin-iliskili-trombositopeni-hit-tani-ve-tedavi-kilavuzu
8. Hess CN, Becker RC, Alexander JH, Lopes RD. An-
tithrombotic therapy in heparin-induced thrombocyto-
penia: guidelines translated for the clinician. J Thromb 
Thrombolysis 2012;34: 552-561.
9. Napolitano LM, Warkentin TE, Almahameed A, Nasr-
away SA. Heparin-induced thrombocytopenia in the 
critical care setting: diagnosis and management. Crit 
Care Med 2006; 34:2898-2911.
10. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during 
cardiopulmonary bypass in patients with previous or 
acute heparin-induced thrombocytopenia and heparin 
antibodies: results of the CHOOSE-ON trial. Ann Tho-
rac Surg 2007;83: 572-577.
11. Dyke CM, Aldea G, Koster A, et al. Off-pump coronary 
artery bypass with bivalirudin for patients with heparin-
induced thrombocytopenia or antiplatelet factor four/
heparin  antibodies. Ann  Thorac  Surg  2007;84:836-
839.
Percutaneous coronary intervention (PCI)
1. For patients with vigorously suspected (or con-
firmed) acute HIT who require cardiac catheteriza-
tion or PCI, we recommend a non-heparin antico-
agulant (bivalirudin [Grade 1B]) over UFH or LMWH 
[Grade 1B].
2. For patients with prior HIT (who are antibody neg-
ative) who require cardiac catheterization or PCI, 
we suggest use of a non-heparin anticoagulant (see 
1) over UFH or LMWH [Grade 2C] [3,6,8].
Anticoagulation in patients with a history of 
HIT
Although recurrence is rare, where a patient with 
prior  HIT  requires  a  period  of  anticoagulation  or 
anticoagulant prophylaxis an alternative to UFH or 
LMWH could be prescribed. Fondaparinux and da-
naparoid can be used [3,6,8].
Hemodialysis
Alternatives (where available) involve saline solu-
tion flushing, citrate, danaparoid,
lepirudin, argatroban, and long-term vitamin K an-
tagonist use. But the most often, danaparoid and 
argatroban have both been used. Guideline (2012) 
is not made any specific recommendations for anti-
coagulation of this patient population [3,6,8].
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